The global oligonucleotide synthesis market, valued at USD 3.66 billion in 2025, is expected to reach approximately USD 14.81 billion by 2035, growing at a robust CAGR of 15%. This rapid expansion is driven by increased demand in gene therapies, diagnostics, and biotechnology advancements, highlighting the sector's transformative potential.

Oligonucleotide Synthesis Market Statical Scope

The oligonucleotide synthesis is a chemical blend run on automation for the quick production of custom single isolated RNA or DNA molecules by utilizing phosphoramidite solution. This chemical designated proportion is used in detritylation, coupling, capping and oxidation. It's popular in ASO therapy, gene synthesis, molecular diagnostics, PCR and DNA sequencing . The enzymatic synthesis is a boon to the market.

The rising trend of precision medicine is leveraging the use of molecular diagnostics kits and CRISPR-based gene editing . This expands the market during the highest prevalence of infectious diseases and cancer conditions. The growth of mRNA-based vaccines, ASOs and siRNA drugs is attracting more healthcare businesses with a high volume of demand for GMP synthesis.

Oligonucleotide Synthesis Market Share, By Region, 2025 (%)

• North America – The North America regional segment dominated the market by 41% of share with the spur of GMP-compliant production potential. The extending diagnostics line, mainly the NGS, probes, and PCR primers, is paving the way for the regional market to rise.
• Europe – Europe covers 24% of the share due to the impeccable transformation in enzymatic synthesis. The empowering, speedy FDA approvals for oligonucleotide drugs and RNA-based therapies are hyping the regional market and signing more contracts for high production.
• Asia-Pacific – Asia Pacific acquires 23% of the share with growing, vast spectrum population genomics projects mainly in Japan and India. This elevates the manufacturing of probes and primers. The powerful therapeutic portfolio is leveraging demand for pure custom RNA/DNA oligos.
• LAMEA- LAMEA leads by 12% of share due to the fine extension of molecular diagnostic potential. The heavy infrastructure investment is supporting the genomic projects, and so the confident rise in the regional segment is strengthened.

Oligonucleotide Synthesis Market Share, By Product & Service Scope, 2025 (%)

• Oligonucleotides – The oligonucleotides segment dominated the market by 39% of share with its large-scale dominance on the CMOs due to outsourcing for commercialization of the product and fame to the modernization in robust synthesis technology.
• Reagents – The segment held 23% of profit due to the unstoppable use of NGS and PCR/qPCR, mainly for genetic screening and diagnostics, which are demanding for specialized reagents. Even the critical conjugation chemistries and modification-based studies call for modern reagents.
• Services – The segment covers 20% of the share as the tech advancements featuring Automated Synthesis Platforms work as services at the production site for the critical long sequencing oligonucleotides. The services in this market involve purification, modification and customized synthesis.
• Equipment/ Synthesizers – The segment leads by 18% due to the perk of automation that enables high-throughput synthesizers. The specific service providers are the customers of the high-quality synthesizers required for their on-site production performance.

Oligonucleotide Synthesis Market Share, By Application, 2025 (%)

• PCR Primers – The PCR primers segment dominated the market by 21% of share, with its powerful dominance as an important member of genetic research. The modern PCR5 technologies are promoting digital PCR, which instantly stimulates the segmental market growth.
• Sequencing – Sequencing segment smartly covers 19% of the share with the high volume of NGS usage for further transcriptomics and genomics research. The oligonucleotide probes play a major role in targeted sequencing and other relevant areas. The high-throughput synthesizers and microarrays is major growth factor for the segmental market.
• PCR Assays and Panels – The segment acquires 18% of share with the valuable transitions in modern techniques, which boost the demand for modified, robust probe-based assays. The popular use of gene panels is welcoming growth and demand for custom oligonucleotide panels.
• Antisense Oligonucleotides – The segment covers 16% of profit due to the commendable improvement in chemical modification. The great delivery mechanisms spur neurodegenerative disease applications that eventually accelerate the segmental market.
• DNA Microarrays – The DNA microarrays segment emerges by 14% of share due to the stellar performance of microarray-based synthesis. This synthesis generates an infinite number of specialized oligonucleotides. While the electrochemical synthesis, MAS, inkjet printing and In Situ synthesis remain profitable procedures to accelerate segmental market growth.
• Fluorescence In Situ Hybridization (FISH) – The segment covers 12% of the share due to the NGS trend in healthcare, as remarkable advancements are demanding the synthetic production of short oligo probes. This is a best-in-class technology to bring brilliant transformation in the market.

Oligonucleotide Synthesis Market Share, By End Use, 2025 (%)

• Academic Research Institutes – The academic research institutes segment dominated the market by 45% share with appreciative partnerships and funding for genomic research. This support unlocked the potential and role of tech applications in the market.
• Pharmaceutical and Biotechnology Companies – The segment acquires 28% of the share with the smart collaboration strategy among the famous leaders like Agilent Technologies, Danaher Corporation and Thermo Fisher Scientific. These partnerships, along with advancements in automation, are fuelling growth in the segmental market.
• Diagnostics Laboratories – The diagnostics laboratories segment covers 27% of the share due to the growing number of genetic disorders. This prevalence requires comprehensive custom oligonucleotide applications. While the unification of AI and automation speeds the segmental market growth.

Top Companies in the Oligonucleotide Synthesis Market

• Thermo Fisher Scientific Inc.
• Merck KGaA
• Danaher
• Revvity Discovery Limited
• Agilent Technologies, Inc.
• Bio-Synthesis, Inc.
• Kaneka Eurogentec S.A.
• LGC Biosearch Technologies
• Biolegio
• Twist Bioscience

Segments Covered in the Report

By Product & Service Scope

• Oligonucleotides
• Equipment/Synthesizer
• Reagents
• Services

By Application

• PCR Primers
• PCR Assays and Panels
• Sequencing
• DNA Microarrays
• Fluorescence In Situ Hybridization (FISH)
• Antisense Oligonucleotides

By End Use

• Academic Research Institutes
• Diagnostic Laboratories
• Pharmaceutical and Biotechnology Companies

By Region

• North America
• Europe
• Asia-Pacific
• LAMEA